|
|
0 1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Æ Ø Å
Ønsker du salgsvekst?
B2B Connect er en plattform hvor bedrifter som trenger salgsmøter kan benytte seg av så mange profesjonelle møtebookere de ønsker, fra en stor pool.
Du betaler kun per booket (og gjennomført) salgsmøte, og pris per salgsmøte bestemmer du selv. Det er ingen bindinger, og ingen oppstarts- eller abonnementsavgift. Prøve oss med kun 3 møter?
| Navn | Universitetet I Oslo |
|---|---|
| Orgnr/født år | 971035854 |
| Ant aksjer | |
| Omsetning | |
| Driftsresultat | |
| Egenkapital | |
| Ant.eiere |
| Navn | Orgnr/født år | Aksjeklasse | Ant aksjer | Andel |
|---|---|---|---|---|
| Ingen registrert | ||||
| Navn | Via | Ant aksjer | Andel | Egenkapital |
|---|---|---|---|---|
| Ingen registrert | ||||
| Navn | Ant aksjer | Andel | Omsetning* | Driftsresultat* | Egenkapital* | Ant.eiere |
|---|---|---|---|---|---|---|
| Unirand AS | 2,025 | 100.0% | 0 | -267 | 2,514 | 1 |
| Inven2 AS | 5,000 | 50.0% | 40,993 | -8,913 | 96,788 | 2 |
| Norsk Medisinsk Syklotronsenter AS | 100 | 20.0% | 18,320 | -2,727 | 3,590 | 3 |
| Visitoslo AS | 1 | 0.5% | 538 | -6 | 30 | 82 |
| Klassekampen AS | 1 | 0.0% | 5 | -0 | 1 | 3,776 |
* Justert for eierandel
| Navn | Ant aksjer | Andel | Omsetning* | Driftsresultat* | Egenkapital* | Ant.eiere |
|---|---|---|---|---|---|---|
| Agiana Pharmaceuticals AS
Via Inven2 AS |
15,000 | 50.0% | 118 | -1,318 | -2,938 | 1 |
| Neonatal Analytics AS
Via Inven2 AS |
15,000 | 50.0% | 0 | 0 | 15 | 1 |
| Newco Inven2 Iii AS
Via Inven2 AS |
15,000 | 50.0% | 1 | |||
| Immunoquest Therapeutics AS
Via Inven2 AS |
10,000 | 33.3% | 0 | 0 | 10 | 3 |
| Baldur Coatings AS
Via Inven2 AS |
25,000 | 25.0% | 88 | 66 | 307 | 3 |
| Dhealth AS
Via Inven2 AS |
58,931 | 20.5% | 192 | -457 | 886 | 66 |
| Cardinor AS
Via Inven2 AS |
22,500 | 19.5% | 870 | -57 | 3,065 | 29 |
| Trygg Natt AS
Via Inven2 AS |
5,293 | 17.6% | 0 | -2 | 4 | 8 |
| Profmof AS
Via Inven2 AS |
17,150 | 16.7% | 922 | 223 | 403 | 6 |
| Aleap AS
Via Inven2 AS |
15,000 | 16.7% | 3,107 | -89 | 368 | 3 |
| Holocare AS
Via Inven2 AS |
10,661 | 16.0% | 381 | -11,285 | 5,219 | 6 |
| Serca Pharmaceuticals AS
Via Inven2 AS |
90,700 | 12.6% | 452 | -559 | 2,072 | 16 |
| Cfire AS
Via Inven2 AS |
15,000 | 10.0% | 0 | 5 | ||
| Sportech AS
Via Inven2 AS |
15,000 | 10.0% | -10 | -16 | 3 | |
| Somsagt AS
Via Inven2 AS |
10,000 | 10.0% | 196 | 22 | -168 | 2 |
| Radfarma AS | 90 | 9.0% | -9 | -137 | 3 | |
| Pone Biometrics AS
Via Inven2 AS |
1,020,452 | 7.5% | 200 | -867 | 3,939 | 56 |
| Pre Diagnostics AS
Via Inven2 AS |
24,167 | 6.9% | 806 | -250 | 478 | 43 |
| Pre Vention AS
Via Inven2 AS |
2,500 | 6.3% | -5 | 63 | 5 | |
| Zelluna Immunotherapy AS
Via Inven2 AS |
735,233 | 6.1% | 479 | -5,707 | 7,503 | 41 |
| Unigeo AS
Via Inven2 AS |
7,500 | 5.8% | 5 | 0 | 3 | 8 |
| Foodcapture AS
Via Inven2 AS |
24,207 | 5.5% | 14 | -96 | 22 | 38 |
| Lundelab AS
Via Inven2 AS |
56 | 5.0% | 0 | -1 | -14 | 2 |
| Prosa Security AS
Via Inven2 AS |
20,786 | 3.2% | 49 | -14 | 5 | 9 |
| Oslo Cancer Cluster Incubator AS
Via Inven2 AS |
6,767 | 2.9% | 614 | 29 | 252 | 4 |
| Adjutec Pharma AS
Via Inven2 AS |
1,324 | 2.9% | 212 | -377 | 522 | 26 |
| Odi Medical AS
Via Inven2 AS |
1,705 | 2.6% | 1 | -288 | 891 | 43 |
| Nordic Brain Tech AS
Via Inven2 AS |
4,439 | 2.5% | 20 | -144 | 590 | 22 |
| Epiguard AS
Via Inven2 AS |
8,880 | 2.2% | 164 | -344 | 251 | 13 |
| Compenso Medtech AS
Via Inven2 AS |
2,222 | 2.0% | 0 | -1 | -1 | 5 |
| Ultimovacs ASA
Via Inven2 AS |
686,082 | 2.0% | -4,191 | 6,169 | 6,384 | |
| Current Eco AS
Via Inven2 AS |
193,607 | 1.7% | 216 | -194 | 522 | 53 |
| Biomolex AS
Via Inven2 AS |
13,716 | 1.6% | 41 | 13 | 3 | 49 |
| Pharmasum Therapeutics AS
Via Inven2 AS |
51,724 | 1.6% | 23 | -24 | 45 | 683 |
| Nextera AS
Via Inven2 AS |
55,527 | 1.5% | 192 | -614 | 224 | 52 |
| Beep Systems AS
Via Inven2 AS |
450 | 1.5% | 0 | 0 | 1 | 2 |
| Stily AS
Via Inven2 AS |
4,500 | 1.5% | 0 | -1 | 3 | 7 |
| Ence AS
Via Inven2 AS |
1,500 | 1.5% | 2 | |||
| Ostomycure AS
Via Inven2 AS |
1,657,733 | 1.0% | -137 | -30 | 34 | |
| Elliptic Laboratories ASA
Via Inven2 AS |
720,835 | 0.7% | 479 | -348 | 2,069 | 2,168 |
| Person-Aiz AS
Via Inven2 AS |
2,457 | 0.6% | 2 | -74 | 6 | 42 |
| Oslo Promotion AS
Via Visitoslo AS |
1 | 0.5% | 0 | 0 | 1 | 1 |
| Oncoinvent ASA
Via Inven2 AS |
105,131 | 0.5% | 31 | -799 | 298 | 446 |
| Prophylix Pharma Holding AS
Via Inven2 AS |
1,678 | 0.3% | -0 | 54 | 40 | |
| Prophylix Pharma Holding AS
Via Inven2 AS |
1,667 | 0.3% | -0 | 54 | 40 | |
| Disputas AS
Via Inven2 AS |
450 | 0.2% | 0 | -0 | 0 | 18 |
| Visitoslo AS
Via Visitoslo AS |
0 | 0.1% | 118 | -1 | 7 | 82 |
| Thor Medical ASA
Via Inven2 AS |
270,624 | 0.1% | 0 | -5 | 318 | 10,877 |
| Novelda AS
Via Inven2 AS |
1,698 | 0.1% | 14 | -156 | 116 | 195 |
| Cruise Norway AS
Via Visitoslo AS |
0 | 0.0% | 0 | 0 | 0 | 51 |
| Klassekampen AS
Via Klassekampen AS |
0 | 0.0% | 0 | -0 | 0 | 3,776 |
| Storebrand ASA
Via Visitoslo AS |
4 | 0.0% | 0 | 0 | 0 | 40,817 |
| Norsk Telegrambyrå AS
Via Klassekampen AS |
0 | 0.0% | 0 | -0 | 0 | 65 |
* Justert for eierandel
